Disclaimer
is Guideline attempts to define principles of practice that should produce high-quality patient
care. It is applicable to specialists, primary care, and providers at all levels. is Guideline
should not be considered exclusive of other methods of care reasonably directed at obtaining the
same results. e ultimate judgment concerning the propriety of any course of conduct must be
made by the clinician aer consideration of each individual patient situation.
Neither IGC, the medical associations, nor the authors endorse any product or service associated
with the distributor of this clinical reference tool.
Abbreviations
AR, allergic rhinitis; FDA, US Food and Drug Administration; HFA, hydrofluoroalkane;
IgE, immunoglobulin E; IgG, immunoglobulin G; INA, intranasal antihistamines; INS,
intranasal steroids; LTRA, leukotriene receptor antagonist; OA, oral antihistamines;
OTC, over the counter; PAR, perennial allergic rhinitis; SAR, seasonal allergic rhinitis
Source
Seidman MD, Gurgel RK, Lin SY, et al. Clinical Practice Guideline: Allergic Rhinitis.
February 2015.
106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at www.GuidelineCentral.com
Copyright © 2014 All rights reserved
AAOHNSALL15013
Evidence Quality and Recommendation Grades
a
Evidence Quality for: Recommendation
Treatment and Harm Diagnosis Strength
A High-quality RCTs Systematic review of
consistent cross-sectional
studies
S Strong
recommendation
B Consistent RCTs Consistent individual
cross-sectional studies
R Recommendation
C Observational studies Nonconsecutive studies,
case-control studies, or
other studies of poor
quality
O Option
D Case reports, consensus opinions
X Exceptional situations with clear benefit
a
See full text guidelines for details.